Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.
Metzeler
Klaus H
KH
Boeck
Stefan
S
Christ
Birgit
B
Hausmann
Andreas
A
Stemmler
Hans-Joachim
HJ
Parhofer
Klaus G
KG
Ostermann
Helmut
H
Hiddemann
Wolfgang
W
Braess
Jan
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics; D000090243:Nucleophosmin; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
D009687:Nuclear Proteins; D003561:Cytarabine; D000090243:Nucleophosmin; D008942:Mitoxantrone; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3